2seventy bio (Nasdaq:TSVT) - Aandelenkoers, Nieuws & Analyse

TSVT Overzicht aandelen

2seventy bio, Inc., een cel- en gentherapiebedrijf, richt zich op het onderzoek, de ontwikkeling en de commercialisering van behandelingen voor kanker in de Verenigde Staten.

Over het bedrijf

TSVT fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	5/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Earnings are forecast to grow 79.38% per year

Earnings have grown 8.9% per year over the past 5 years

Risicoanalyse

Shareholders have been diluted in the past year

2seventy bio, Inc. Concurrenten

TScan Therapeutics

NasdaqGM:TCRX

US$262.2m

AVITA Medical

NasdaqCM:RCEL

US$270.0m

Editas Medicine

NasdaqGS:EDIT

US$239.3m

Heron Therapeutics

NasdaqCM:HRTX

US$270.0m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor 2seventy bio
Historische aandelenkoersen
Huidige aandelenkoers	US$4.40
52 Week Hoogtepunt	US$6.40
52 Week Laag	US$1.54
Bèta	1.78
11 maand verandering	-8.52%
3 maanden verandering	9.45%
1 Jaar Verandering	78.14%
33 jaar verandering	-89.00%
5 jaar verandering	n/a
Verandering sinds IPO	-68.05%

Recent nieuws en updates

There's No Escaping 2seventy bio, Inc.'s (NASDAQ:TSVT) Muted Revenues

Oct 03

Recent updates

There's No Escaping 2seventy bio, Inc.'s (NASDAQ:TSVT) Muted Revenues

Oct 03

2seventy bio, Inc.'s (NASDAQ:TSVT) Share Price Is Matching Sentiment Around Its Revenues

Jul 04

Downgrade: Here's How Analysts See 2seventy bio, Inc. (NASDAQ:TSVT) Performing In The Near Term

May 11

2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround

Apr 03

These Analysts Just Made A Massive Downgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) EPS Forecasts

Mar 07

2seventy bio, Inc. (NASDAQ:TSVT) Held Back By Insufficient Growth Even After Shares Climb 49%

Feb 06

Here's Why We're Watching 2seventy bio's (NASDAQ:TSVT) Cash Burn Situation

Jan 17

2seventy bio, Inc. (NASDAQ:TSVT) Shares Fly 44% But Investors Aren't Buying For Growth

Dec 13

Industry Analysts Just Made A Dazzling Upgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts

May 05

Industry Analysts Just Upgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts By 12%

Mar 21

2seventy bio, Inc. (NASDAQ:TSVT) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates

Mar 19

Time To Worry? Analysts Just Downgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Outlook

Aug 12

2seventy bio GAAP EPS of -$2.02 misses by $0.09, revenue of $13.48M misses by $3.04M

Aug 10

Rendement voor aandeelhouders

	TSVT	US Biotechs	US Markt
7D	-11.6%	-0.7%	-1.6%
1Y	78.1%	19.8%	30.8%

Rendement versus industrie: TSVT exceeded the US Biotechs industry which returned 19.8% over the past year.

Rendement versus markt: TSVT exceeded the US Market which returned 30.8% over the past year.

Prijsvolatiliteit

Is TSVT's price volatile compared to industry and market?
TSVT volatility
TSVT Average Weekly Movement	8.4%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: TSVT has not had significant price volatility in the past 3 months compared to the US market.

Volatiliteit in de loop van de tijd: TSVT's weekly volatility (8%) has been stable over the past year.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2021	274	Chip Baird	www.2seventybio.com

2seventy bio, Inc, een cel- en gentherapiebedrijf, richt zich op het onderzoek, de ontwikkeling en de commercialisering van behandelingen voor kanker in de Verenigde Staten. De productpijplijn van het bedrijf omvat Abecma, een chimere antigen receptor T-cel productkandidaat voor de behandeling van multipel myeloom. Het heeft een samenwerkingsovereenkomst met Bristol Myers Squibb Company.

2seventy bio, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van 2seventy bio zich tot de beurswaarde?
TSVT fundamentele statistieken
Marktkapitalisatie	US$226.59m
Inkomsten(TTM)	-US$156.25m
Inkomsten(TTM)	US$44.12m

5.1x

P/S-verhouding

-1.5x

Koers/Winstverhouding

Is TSVT overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
TSVT resultatenrekening (TTM)
Inkomsten	US$44.12m
Kosten van inkomsten	US$178.53m
Brutowinst	-US$134.41m
Overige uitgaven	US$21.84m
Inkomsten	-US$156.25m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Nov 14, 2024

Winst per aandeel (EPS)	-3.03
Brutomarge	-304.66%
Nettowinstmarge	-354.16%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde TSVT op de lange termijn?

Bekijk historische prestaties en vergelijking

TSVT Overzicht aandelen

Beloningen

Risicoanalyse

2seventy bio, Inc. Concurrenten

NasdaqGM:TCRX

US$262.2m

NasdaqCM:RCEL

US$270.0m

NasdaqGS:EDIT

US$239.3m

NasdaqCM:HRTX

US$270.0m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

2seventy bio, Inc. to Report Q3, 2024 Results on Nov 14, 2024

There's No Escaping 2seventy bio, Inc.'s (NASDAQ:TSVT) Muted Revenues

Consensus estimates of losses per share improve by 11%

Price target decreased by 25% to US$8.25

Consensus EPS estimates upgraded to US$1.08 loss, revenue downgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Recent updates

2seventy bio, Inc. to Report Q3, 2024 Results on Nov 14, 2024

There's No Escaping 2seventy bio, Inc.'s (NASDAQ:TSVT) Muted Revenues

Consensus estimates of losses per share improve by 11%

Price target decreased by 25% to US$8.25

Consensus EPS estimates upgraded to US$1.08 loss, revenue downgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

2seventy bio, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Forecast to breakeven in 2026

2seventy bio, Inc.'s (NASDAQ:TSVT) Share Price Is Matching Sentiment Around Its Revenues

Consensus revenue estimates increase by 16%

New minor risk - Profitability

Downgrade: Here's How Analysts See 2seventy bio, Inc. (NASDAQ:TSVT) Performing In The Near Term

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Forecast to breakeven in 2026

2seventy bio, Inc., Annual General Meeting, Jun 10, 2024

2seventy bio, Inc. to Report Q1, 2024 Results on May 15, 2024

U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio’S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $15 million.

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $20 million.

2seventy bio, Inc. Announces Board Appointments

FDA Advisory Committee Votes in Favor of Bristol-Myers Squibb Company and 2seventy bio, Inc. Abecma for Triple-Class Exposed Multiple Myeloma in Further Lines of Therapy

Consensus revenue estimates fall by 24%

New minor risk - Shareholder dilution

These Analysts Just Made A Massive Downgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) EPS Forecasts

New minor risk - Profitability

Third quarter 2023 earnings released: US$1.40 loss per share (vs US$1.76 loss in 3Q 2022)

Forecast to breakeven in 2025

2seventy bio, Inc. to Report Q4, 2023 Results on Mar 05, 2024

2seventy bio, Inc. (NASDAQ:TSVT) Held Back By Insufficient Growth Even After Shares Climb 49%

Bristol Myers Squibb and 2seventy bio, Inc. Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study

Price target increased by 33% to US$10.67

2seventy bio, Inc. Announces Executive and Board Changes

Here's Why We're Watching 2seventy bio's (NASDAQ:TSVT) Cash Burn Situation

President recently sold US$280k worth of stock

Bristol Myers Squibb and 2seventy bio, Inc. Announce Results from the Preplanned Final Progression-Free Survival Analysis of KarMMa-3

2seventy bio, Inc. (NASDAQ:TSVT) Shares Fly 44% But Investors Aren't Buying For Growth

High number of new and inexperienced directors

Bristol Myers Squibb and 2seventy bio, Inc Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Early Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

2Seventy Bio, Inc. Does Not Expect to Achieve the Original Revenue Guidance for 2023

2seventy bio, Inc. Announces Goodwill Impairment Charges for the Third Quarter Ended September 30, 2023

2seventy bio, Inc. to Report Q3, 2023 Results on Nov 14, 2023

2seventy bio, Inc. Plans to Reduce its Workforce by Approximately 40%

2Seventy Bio, Inc. Announces Resignation of Nick Leschly as CEO

President recently sold US$51k worth of stock

Consensus estimates of losses per share improve by 15%

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

President recently sold US$55k worth of stock

2seventy bio, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Price target decreased by 11% to US$25.00

2seventy bio Announces Clinical Study Pause of PLAT-08 Trial of SC-DARIC33 in Acute Myeloid Leukemia

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Industry Analysts Just Made A Dazzling Upgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts

Consensus revenue estimates increase by 33%

Consensus revenue estimates increase by 12%

Industry Analysts Just Upgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts By 12%

2seventy bio, Inc. (NASDAQ:TSVT) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Bristol Myers Squibb and 2Seventy Bio Announce the First Publication and Presentation of Positive Results from KarMMa-3